Cancer MoonShot 2020 Initiative Spurs Immunotherapy Research and Integrated Logistics Need

Thu, Jan 19, 2017 | By Mark W. Sawicki, Ph.D., Chief Commercial Officer, Cryoport

Providing $6.3 billion in funding for medical innovation to expedite the discovery, development and delivery of new treatments and cures, the 21st Century Cures Act (Cures) received overwhelming Congressional approval and was signed into law in December 2016.

The Cancer MoonShot 2020 Program, a $1.8 billion initiative of Cures, aims to accelerate the potential of combination immunotherapy as the next-generation standard of care in cancer patients. The program will involve initiating randomized Phase II trials in 20,000 patients at all stages of disease in 20 tumor types within the next 36 months. These findings will inform Phase III trials and drive development of an effective, vaccine-based immunotherapy to combat cancer by 2020. The moonshot: To win the war on cancer and, by 2020, manage cancer as a chronic disease such as diabetes or asthma.

As greater funding drives immunotherapy research forward, there will be a growing need for an integrated logistics strategy and solutions that can facilitate the manufacture, transport and storage of these temperature-sensitive biologics for the clinical trials and eventual commercialization. Ultimately, partnering with a reliable logistics partner that understands the complexities of immunotherapy transport will ensure that the greatest number of patients benefit from these next-generation therapies.

Read our blog for the latest news on cold chain logistics issues.

Questions or comments? We welcome your feedback!

Email Us

Tags: Biopharma Industry News

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC